GSK has acquired full global rights to Chimagen Biosciences' trispecific T-cell engager programme for multiple myeloma in a transaction worth up to $750 million.

The clearance extends Wandercraft’s self-balancing exoskeleton technology beyond supervised rehabilitation, allowing eligible adults with spinal cord injuries to use Eve for hands-free upright mobility and daily activities with a trained companion.

The approval provides adults who have received at least one prior line of therapy with a new iberdomide-based combination, supported by higher minimal residual disease-negative complete response rates than the comparator regimen in EXCALIBER-RRMM.

New formulation expands Sanofi’s Sarclisa portfolio by offering a subcutaneous delivery option across multiple myeloma treatment settings, including newly diagnosed, relapsed and refractory disease.

Combination therapy demonstrates significant improvements in progression-free and overall survival in adults after at least one prior treatment, offering a new standard-of-care option.